Medication risk resolved - not just identified

When a case manager identifies medication-related risk in a claim, the available options are often limited. The most common lever is to decline or restrict funding for the medication in question. But this approach creates significant problems.

Declining funding doesn't remove the clinical risk. The claimant may still access the medication through PBS, another prescriber, or out-of-pocket. The underlying prescribing pattern remains unchanged. And the insurer has now created an adversarial dynamic with the claimant and potentially with the treating doctor - all while the actual risk to the claim continues unmanaged.

This is the dilemma IMM was built to resolve.

Instead of forcing insurers into a binary funding decision, IMM creates a third pathway. Our pharmacists work directly with treating doctors - pharmacist to prescriber, clinical professional to clinical professional - to address medication risk at its source.

When a high-risk medication is deprescribed through clinical engagement, or a dangerous interaction is resolved by adjusting the treatment regimen, the risk doesn't just appear managed on paper. It is genuinely resolved. The medication is ceased, reduced, or replaced with a safer alternative - with the treating doctor's agreement and implementation.

This is what the 81% prescriber implementation rate represents. It's not a compliance metric. It's evidence that treating doctors trust IMM's pharmacists enough to act on their recommendations - because those recommendations come from a place of clinical independence, specialist expertise, and genuine concern for the patient's wellbeing.

For the injured person: Safer medication use. Fewer side effects like sedation, cognitive impairment, and fatigue. Better engagement with rehabilitation. A clearer path to recovery and return to work.

For the insurer: The medication risk that was driving claim complexity has been clinically resolved - not just flagged in a report. Funding decisions are supported by independent, evidence-based pharmacist input. Long-tail claim risk is reduced because the root cause has been addressed, not avoided.

For the treating doctor: A collaborative, pharmacist-led conversation about medication optimisation - not a funding decline from an insurer. Treating doctors engage because the process is clinical, not adversarial. They retain prescribing authority while benefiting from specialist pharmacist input they may not otherwise have access to.